The Journal of Nuclear Medicine - JNM

The Journal of Nuclear Medicine - JNM Founded in 1960, The Journal of Nuclear Medicine is the world’s leading nuclear medicine, molecular i

According to new data announced by Clarivate in the 2020 Journal Citation Reports™ (released in June 2021), JNM ranks third in impact among 134 medical imaging journals worldwide. Impact factor – 10.057
Five-year impact factor – 8.573
Immediacy index – 4.011
Total citations – 32,949
Eigenfactor Score – 0.03249
Article Influence Score – 2.19

Tumor absorbed dose—both in cycle 1 and cumulatively throughout the course of treatment—is an independent predictor of P...
09/08/2026

Tumor absorbed dose—both in cycle 1 and cumulatively throughout the course of treatment—is an independent predictor of PFS and OS in patients with grade 1 or grade 2 neuroendocrine tumors treated with ¹⁷⁷Lu-DOTATATE. https://ow.ly/Pq6I50ZzPpU

Dynamic changes in ⁶⁸Ga-HER2 PET/CT uptake during neoadjuvant therapy provide an effective early indicator of therapeuti...
09/04/2026

Dynamic changes in ⁶⁸Ga-HER2 PET/CT uptake during neoadjuvant therapy provide an effective early indicator of therapeutic sensitivity in HER2-positive breast cancer. https://ow.ly/yprn50ZzPka

The newly developed E. coli dihydrofolate reductase (eDHFR)-radioiodinated trimethoprim system demonstrates theranostic...
09/02/2026

The newly developed E. coli dihydrofolate reductase (eDHFR)-radioiodinated trimethoprim system demonstrates theranostic potential, selectively targeting eDHFR-expressing cells with minimal off-target uptake. https://ow.ly/5RlG50ZzPiS

The French early-access program confirms a favorable benefit–risk profile for ¹⁷⁷Lu-PSMA-617 in a real-world mCRPC popul...
08/31/2026

The French early-access program confirms a favorable benefit–risk profile for ¹⁷⁷Lu-PSMA-617 in a real-world mCRPC population, supporting its integration into routine clinical care. Read more: https://ow.ly/s7cz50ZzPh4

How should next-generation radioligand conjugates be developed to move beyond modular radiochemistry and achieve broader...
08/26/2026

How should next-generation radioligand conjugates be developed to move beyond modular radiochemistry and achieve broader clinical translation as radiopharmaceutical platforms? https://ow.ly/ko5K50ZzPaW

Update to “Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cance...
08/24/2026

Update to “Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.” https://ow.ly/EA0Q50ZzPao

Results from the RESIST-PC phase 2 trial: There are no differences in the estimated absorbed dose to the normal organs a...
08/21/2026

Results from the RESIST-PC phase 2 trial: There are no differences in the estimated absorbed dose to the normal organs at risk and selected lesions between the 2 different injected activities groups. https://ow.ly/SzYn50ZzP9C

The OPTIMAL-PSMA trial aims to determine whether a dose-intensified regimen of ¹⁷⁷Lu-PSMA-597 is safe and improves respo...
08/19/2026

The OPTIMAL-PSMA trial aims to determine whether a dose-intensified regimen of ¹⁷⁷Lu-PSMA-597 is safe and improves response and survival outcomes compared with the standard dosing regimen. Learn more: https://ow.ly/ZjpF50ZzP7Q

Neuroinflammatory PET in epilepsy: Prospects for epileptogenic zone localization and presurgical planning. https://ow.ly...
08/17/2026

Neuroinflammatory PET in epilepsy: Prospects for epileptogenic zone localization and presurgical planning. https://ow.ly/w95450ZzP5t

Address

Reston, VA
20190

Website

Alerts

Be the first to know and let us send you an email when The Journal of Nuclear Medicine - JNM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category